Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma
- 29 June 2021
- journal article
- case report
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 48 (11) , 1423-1426
Abstract
Talimogene laherparepvec (TVEC) is a genetically modified herpes simplex virus‐1 approved as an intralesional oncolytic immunotherapy for the treatment of advanced melanoma. Cutaneous reactions at the site of injection may mimic recurrent or progressive melanoma; histopathological findings have included chronic granulomatous dermatitis, neutrophilic dermatitis, lymphocytic dermatitis, and pigment incontinence. We report a 39‐year‐old male with metastatic stage IIIc melanoma treated with TVEC with clinical regression of melanoma lesions that later developed pink nodules at sites of prior injection. Histopathology demonstrated a nodular mononuclear infiltrate that stained strongly and diffusely with CD45 and CD20 with a surrounding rim of CD3‐positive T‐cells. Immunoglobulin gene rearrangement was negative for a clonal B‐cell population. To our knowledge, this is the first report of a pseudolymphomatous reaction mimicking recurrent melanoma after TVEC therapy.Keywords
This publication has 14 references indexed in Scilit:
- Extensive Pigment Incontinence Mimicking Persistent Melanoma After Talimogene Laherparepvec TherapyJAMA Dermatology, 2019
- The histological spectrum of talimogene laherparepvec (TVEC) injections-Neutrophilic and chronic granulomatous dermatitisJournal of Cutaneous Pathology, 2019
- Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution ExperienceAnnals of Surgical Oncology, 2018
- Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, in‐transit melanomaJournal of Cutaneous Pathology, 2018
- Drug induced pseudolymphomaSeminars in Diagnostic Pathology, 2018
- Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastasesJournal of Cutaneous Pathology, 2017
- Interstitial granulomatous dermatitis during talimogen laherparepvec treatmentMelanoma Research, 2017
- Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet’s-like InfiltrateJAMA Dermatology, 2017
- Phenytoin induced cutaneous B cell pseudolymphomaIndian Journal of Dermatology, 2015
- EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferationsLeukemia, 2012